bullish
IMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer Trial
On November 7, 2024, Imunon, Inc. (IMNN) announced financial results for the third quarter of 2024 and provided a business update. Following...
What is covered in the Full Insight:
- Business Update
- Preparations for Phase 3 Ovarian Cancer Trial
- Financial Update
- Clinical Results from OVATION 2 Trial
- Conclusion and Future Outlook
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
x